

CYP3A4 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP7788c

Specification

CYP3A4 Antibody (Center) Blocking Peptide - Product Information

Primary Accession P08684

CYP3A4 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 1576

Other Names

Cytochrome P450 3A4, 11413-, 8-cineole 2-exo-monooxygenase, Albendazole monooxygenase, Albendazole sulfoxidase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450-PCN1, Nifedipine oxidase, Quinine 3-monooxygenase, Taurochenodeoxycholate 6-alpha-hydroxylase, CYP3A4, CYP3A3

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP7788c was selected from the Center region of human CYP3A4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CYP3A4 Antibody (Center) Blocking Peptide - Protein Information

Name CYP3A4 {ECO:0000303|PubMed:11470997, ECO:0000312|HGNC:HGNC:2637}

Function

A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:<a href="http://www.uniprot.org/citations/20702771"



```
target=" blank">20702771</a>, PubMed:<a href="http://www.uniprot.org/citations/19965576"
target="blank">19965576</a>, PubMed:<a href="http://www.uniprot.org/citations/21490593"
target="blank">21490593</a>, PubMed:<a href="http://www.uniprot.org/citations/21576599"
target=" blank">21576599</a>). Mechanistically, uses molecular oxygen inserting one oxygen
atom into a substrate, and reducing the second into a water molecule, with two electrons provided
by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the
hydroxylation of carbon-hydrogen bonds (PubMed:<a
href="http://www.uniprot.org/citations/2732228" target="_blank">2732228</a>, PubMed:<a href="http://www.uniprot.org/citations/14559847" target="_blank">14559847</a>, PubMed:<a
href="http://www.uniprot.org/citations/12865317" target="_blank">12865317</a>, PubMed:<a
href="http://www.uniprot.org/citations/15373842" target="blank">15373842</a>, PubMed:<a
href="http://www.uniprot.org/citations/15764715" target="blank">15764715</a>, PubMed:<a
href="http://www.uniprot.org/citations/21576599" target="blank">21576599</a>, PubMed:<a
href="http://www.uniprot.org/citations/21490593" target=" blank">21490593</a>). Exhibits high
catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta- estradiol
(E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position
(PubMed:<a href="http://www.uniprot.org/citations/11555828" target=" blank">11555828</a>,
PubMed:<a href="http://www.uniprot.org/citations/14559847" target="_blank">14559847</a>,
PubMed:<a href="http://www.uniprot.org/citations/12865317" target="blank">12865317</a>).
Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone
(PubMed:<a href="http://www.uniprot.org/citations/2732228" target=" blank">2732228</a>,
PubMed: <a href="http://www.uniprot.org/citations/15373842" target="blank">15373842</a>,
PubMed:<a href="http://www.uniprot.org/citations/15764715" target="_blank">15764715</a>,
PubMed:<a href="http://www.uniprot.org/citations/22773874" target="blank">22773874</a>).
Metabolizes testosterone to less biologically active 2beta- and 6beta- hydroxytestosterones
(PubMed:<a href="http://www.uniprot.org/citations/2732228" target=" blank">2732228</a>,
PubMed:<a href="http://www.uniprot.org/citations/15373842" target="blank">15373842</a>,
PubMed: <a href="http://www.uniprot.org/citations/15764715" target="blank">15764715</a>).
Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated
cholesterol at the C- 4beta position, and side chain hydroxylated cholesterol at the C-25 position,
likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed: <a
href="http://www.uniprot.org/citations/21576599" target=" blank">21576599</a>). Catalyzes
bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:<a
href="http://www.uniprot.org/citations/9435160" target=" blank">9435160</a>). Catalyzes the
epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed: <a
href="http://www.uniprot.org/citations/19965576" target=" blank">19965576</a>). Metabolizes
endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-
epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid
system signaling (PubMed:<a href="http://www.uniprot.org/citations/20702771"
target=" blank">20702771</a>). Plays a role in the metabolism of retinoids. Displays high
catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the
biosynthesis of all-trans-retinoic acid (atRA) (PubMed:<a
href="http://www.uniprot.org/citations/10681376" target=" blank">10681376</a>). Further
metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance
(PubMed:<a href="http://www.uniprot.org/citations/11093772" target=" blank">11093772</a>).
Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo- monooxygenase for plant
lipid 1,8-cineole (eucalyptol) (PubMed: <a href="http://www.uniprot.org/citations/11159812"
target=" blank">11159812</a>). Metabolizes the majority of the administered drugs. Catalyzes
sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:<a
href="http://www.uniprot.org/citations/10759686" target=" blank">10759686</a>). Hydroxylates
antimalarial drug quinine (PubMed: <a href="http://www.uniprot.org/citations/8968357"
target=" blank">8968357</a>). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:<a
href="http://www.uniprot.org/citations/11695850" target="_blank">11695850</a>). Also involved
in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active
hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:<a
href="http://www.uniprot.org/citations/29461981" target=" blank">29461981</a>).
```



Cellular Location

Endoplasmic reticulum membrane; Single-pass membrane protein. Microsome membrane; Single-pass membrane protein

Tissue Location

Expressed in prostate and liver. According to some authors, it is not expressed in brain (PubMed:19094056). According to others, weak levels of expression are measured in some brain locations (PubMed:19359404, PubMed:18545703). Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).

CYP3A4 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

CYP3A4 Antibody (Center) Blocking Peptide - Images

CYP3A4 Antibody (Center) Blocking Peptide - Background

CYP3A4, is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monoxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs which are are used today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens.

CYP3A4 Antibody (Center) Blocking Peptide - References

Sandanaraj, E., Clin. Cancer Res. 14 (21), 7116-7126 (2008) Nelson, D.R., Pharmacogenetics 14 (1), 1-18 (2004) Inoue, K., Ipn. J. Hum. Genet. 37 (2), 133-138 (1992)